» Articles » PMID: 39505806

Ginger Extract Improves Cognitive Dysfunction Via Modulation of Gut Microbiota-Derived Short-Chain Fatty Acids in D-Galactose/Ovariectomy-Induced Alzheimer-Like Disease

Overview
Journal Mol Neurobiol
Date 2024 Nov 6
PMID 39505806
Authors
Affiliations
Soon will be listed here.
Abstract

Alzheimer's disease (AD) is the most common form of dementia with complex causes and limited treatment options. Recent research has suggested a connection between the progression of AD and the activity of gut microbiota. Ginger, a plant known for its anti-inflammatory, antioxidant, and neuroprotective properties, has gained attention as a potential treatment for alleviating AD symptoms. In this study, we induced an AD model in female rats through ovariectomy and D-galactose injection and then investigated the protective effects of oral administration of ginger ethanolic extract. We assessed changes in short-chain fatty acids (SCFAs), learning and memory abilities, neuroinflammatory markers in plasma, and the hippocampus, as well as histological changes in the intestine and hippocampus in sham-operated, diseased, and treatment groups. Oral administration of ginger ethanolic extract improved gut microbiota activity, increased SCFA levels, and enhanced the expression of tight junction proteins. Additionally, ginger extract reduced the concentrations of TNF-α and IL-1β in both plasma and the hippocampus. Furthermore, it significantly reduced cell death and amyloid plaque deposition in the hippocampal tissue. These physiological changes resulted in improved performance in learning and memory tasks in rats treated with ginger compared with the disease group. These findings provide compelling evidence for the beneficial effects of ginger on the gut-brain axis, leading to improvements in learning and memory through the reduction of neuroinflammation.

References
1.
Frozza R, Lourenco M, De Felice F . Challenges for Alzheimer's Disease Therapy: Insights from Novel Mechanisms Beyond Memory Defects. Front Neurosci. 2018; 12:37. PMC: 5808215. DOI: 10.3389/fnins.2018.00037. View

2.
Angelopoulou E, Paudel Y, Papageorgiou S, Piperi C . APOE Genotype and Alzheimer's Disease: The Influence of Lifestyle and Environmental Factors. ACS Chem Neurosci. 2021; 12(15):2749-2764. DOI: 10.1021/acschemneuro.1c00295. View

3.
Gibbs R . Estrogen therapy and cognition: a review of the cholinergic hypothesis. Endocr Rev. 2009; 31(2):224-53. PMC: 2852210. DOI: 10.1210/er.2009-0036. View

4.
Pistollato F, Sumalla Cano S, Elio I, Vergara M, Giampieri F, Battino M . Role of gut microbiota and nutrients in amyloid formation and pathogenesis of Alzheimer disease. Nutr Rev. 2016; 74(10):624-34. DOI: 10.1093/nutrit/nuw023. View

5.
Pluta R, Ulamek-Koziol M, Januszewski S, Czuczwar S . Gut microbiota and pro/prebiotics in Alzheimer's disease. Aging (Albany NY). 2020; 12(6):5539-5550. PMC: 7138569. DOI: 10.18632/aging.102930. View